AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.

WILMINGTON, Del., May 02, 2025--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose ...

KALOS and LOGOS trials with 4,400 patients showed Breztri improved lung function over dual ICS/LABA therapies. No new safety concerns were found in Breztri Phase 3 asthma trials; all primary ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...

KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI ...

WILMINGTON, Del., May 02, 2025--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose ...

Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan.

Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) is a prescription drug used to treat COPD. It comes with an inhaler device for breathing the drug into your lungs. You’ll ...

(Sharecast News) - AstraZeneca announced on Friday that its inhaled triple-combination therapy 'Breztri Aerosphere' met all primary endpoints in two phase three trials, delivering statistically ...

May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy Breztri Aerosphere ...

MANILA, Philippines — Network giant Globe Telecom Inc. relied on its non-telco ventures, particularly GCash, to grow its profit in the first quarter of the year, as the company suffered revenue ...